Identifying the onset and duration of anti-allergic and anti-inflammatory products can be vital to your development success. For over 30 years, the Ora Conjunctival Allergen Challenge Model (Ora-CAC®) has been used to evaluate every anti-allergic agent for the treatment of allergic conjunctivitis. In this webinar, Paul Gomes (Vice President, Allergy) will share various applications of this model such as Phase 2 dose ranging, Phase 3 pivotals, and clinical bioequivalence. He will also discuss utilization of the Ora-CAC® Model as a high through-put screen of anti-inflammatory agents. Click on the link below to register for the webinar.
Tuesday, December 10th at 12:00pm-1:00pm EST